{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T18:04:12Z","timestamp":1783101852365,"version":"3.54.6"},"reference-count":14,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"UVA Cancer Center"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.ygyno.2017.05.006","type":"journal-article","created":{"date-parts":[[2017,5,10]],"date-time":"2017-05-10T07:02:07Z","timestamp":1494399727000},"page":"346-350","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["A SEER-Medicare analysis of the impact of metformin on overall survival in ovarian cancer"],"prefix":"10.1016","volume":"146","author":[{"given":"Christine","family":"Garcia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Camacho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Balkrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leigh A.","family":"Cantrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2017.05.006_bb0005","author":"SEER Stat Fact Sheets"},{"key":"10.1016\/j.ygyno.2017.05.006_bb0010","series-title":"Principles and Practice of Gynecologic Oncology","author":"Barakat","year":"2013"},{"key":"10.1016\/j.ygyno.2017.05.006_bb0015","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2014-000049","article-title":"Metformin and breast and gynecological cancer risk among women with diabetes","volume":"3","author":"Soffer","year":"2015","journal-title":"BMJ Open Diabetes Res. Care"},{"issue":"8","key":"10.1016\/j.ygyno.2017.05.006_bb0020","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/OGX.0000000000000092","article-title":"Metformin and gynecologic cancers","volume":"68","author":"Stine","year":"2014","journal-title":"Obstet. Gynecol. Surv."},{"issue":"1","key":"10.1016\/j.ygyno.2017.05.006_bb0025","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ygyno.2009.09.024","article-title":"Metformin is a potent inhibitor of endometrial cancer cell proliferation-implications for a novel treatment strategy","volume":"116","author":"Cantrell","year":"2010","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.05.006_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2014.10.026","article-title":"Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models","volume":"212","author":"Lengyel","year":"2015","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"5","key":"10.1016\/j.ygyno.2017.05.006_bb0035","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1593\/neo.11148","article-title":"Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo","volume":"13","author":"Rattan","year":"2011","journal-title":"Neoplasia"},{"key":"10.1016\/j.ygyno.2017.05.006_bb0040","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ygyno.2011.06.038","article-title":"Use of metformin and the risk of ovarian cancer: a case-control analysis","volume":"123","author":"Bodmer","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.05.006_bb0045","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/AOG.0b013e3182393ab3","article-title":"Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity","volume":"119","author":"Romero","year":"2012","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2017.05.006_bb0050","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/cncr.27706","article-title":"Metformin intake is associated with better survival in ovarian cancer: a case-control study","volume":"119","author":"Kumar","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2017.05.006_bb0055","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1111\/1475-6773.12182","article-title":"Methods for constructing and assessing propensity scores","volume":"49","author":"Garrido","year":"2014","journal-title":"Health Serv. Res."},{"issue":"8","key":"10.1016\/j.ygyno.2017.05.006_bb0060","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/pds.1230","article-title":"Methods for evaluation of medication adherence and persistence using automated databases","volume":"15","author":"Andrade","year":"2006","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"16","key":"10.1016\/j.ygyno.2017.05.006_bb0065","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1200\/JCO.2015.63.3511","article-title":"Metformin use and survival of patients with pancreatic cancer: a cautionary lesson","volume":"34","author":"Chaiteerakij","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.05.006_bb0070","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1158\/1078-0432.CCR-11-2994","article-title":"Metformin use is associated with better survival of diabetic patients with pancreatic cancer","volume":"18","author":"Sadeghi","year":"2012","journal-title":"Clin. Cancer Res."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825817308478?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825817308478?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,2]],"date-time":"2018-09-02T01:23:06Z","timestamp":1535851386000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825817308478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S0090825817308478"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2017.05.006","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A SEER-Medicare analysis of the impact of metformin on overall survival in ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2017.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}